News Focus
News Focus
icon url

DewDiligence

07/24/17 5:55 PM

#212596 RE: biomaven0 #212594

There are several moving parts in play, but clearly vendors of the reference drugs are going to have less pricing leverage with payers than they did before FoBs arrived.